Physician Office Sample CMS-1500 Claim Form



The CMS-1500 claim form is the standard claim form used by physician offices to bill many government and private insurers. This sample is intended to educate you on completing the form for billing ENTYVIO and associated services.

- (A) Diagnosis Code | Box 21 Document appropriate ICD-10-CM diagnosis code(s) corresponding to the patient's diagnosis. Line A—primary diagnosis code
- B Product Information | Box 24 Supplemental information may be entered in the shaded section. Providers must verify information requirements with the payer
- **C Product Code | Box 24D** Document the appropriate HCPCS code for infusion of ENTYVIO (eg, J code)
- D Procedure Code | Box 24D Use the CPT® code representing the procedure performed, as required by the payer
- E Diagnosis Pointer | Box 24E Specify diagnosis, from Box 21, related to each CPT/HCPCS code listed in Box 24D. This may be in a letter or number depending on the payer
- F Service Units | Box 24G Report number of units (eg, 300 units = 300 mg)

Click <u>here</u> for a CMS-1500 CLAIM FORM you can fill out.

This billing guide does not represent a promise or guarantee of coverage and payment for any individual patient or treatment. Correct coding is the responsibility of the provider submitting a claim for the item or service. Please check with the payer to verify codes and any special billing requirements.



If you have questions about completing a claim form for ENTYVIO, call *EntyvioConnect* at **1-855-ENTYVIO** (1-855-368-9846), Monday to Friday, from 8 AM to 8 PM ET (except holidays).

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Please see Indications and Important Safety Information on the next page.

	UNIFORM CLAIM COMM	I FORM	2								
PICA	Otti Ottii ODiii Odiiii	1122 (11000) 021	•						PICA		
	DICAID TRICARE	CHAM		PLAN FECA BLK LUI	OTHER	1a, INSURED'S I D. N	JUMBER	(Fo	or Program in Item 1)	
the same of the sa	(ID#/DoD#)	(Membe			(IDII)						
2. PATIENT'S NAME (Last	Name, First Name, Middle	Initial)	3. PATIENTS BIF		SEX	4. INSURED'S NAME	(Last Name, Firs	Name, Midd	(e Initial)		
5. PATIENT'S ADDRESS (No., Street)		6. PATIENT REL	ATIONSHIP TO INS	F	7. INSURED'S ADDRI	ESS (No. Street			_	
			Self Spor		Other						
CITY		STAT				CITY			STATE		
ZIP CODE	TELEPHONE (Incl.	ide Asan Cada)				ZIP CODE	- Inc				
ZIF CODE	()	Ade Area Code)				ZIP CODE	TEL	EPHONE (Inc	clude Area Code)		
9. OTHER INSURED'S NA	ME (Last Name, First Nam	e, Middle Initial)	10. IS PATIENT'S	CONDITION RELA	TED TO:	11. INSURED'S POLIC	CY GROUP OR	ECA NUMBE	A	_	
						C)					
a. OTHER INSURED'S PO	LICY OR GROUP NUMBER	9		7 (Current or Previ		a. INSURED'S DATE	OF BIRTH YY		SEX		
b. RESERVED FOR NUCC USE				b. AUTO ACCIDENT?			M F				
THE STATE OF THE S				PLACE (State)			b. OTHER CLAIM ID (Designated by NUCC)				
c. RESERVED FOR NUCC	USE		c. OTHER ACCID	ENT?		c. INSURANCE PLAN	NAME OR PRO	GRAM NAME			
				YES NO							
d. INSURANCE PLAN NAME OR PROGRAM NAME			10d. CLAIM COD	ES (Designated by	NUCC)	d. IS THERE ANOTHE	7				
	READ BACK OF FORM BEFORE COMPLETING & S 12 PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the releas 10 process this claim. I also request payment of government benefits either to my				SIGNING THIS FORM.			YES NO If yes, complete items 9, 9a, and 9d. 13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize			
12 PATIENT'S OR AUTHO to process this claim. I a below.	RIZED PERSON'S SIGNA so request payment of gove	TURE I authorize the roment benefits eith	e release of any medic er to myself or to the p	cal or other informati arty who accepts as	on necessary signment	payment of medica services described	al benefits to the	undersigned pl	hysician or supplier t	for	
SIGNED			DATE			SIGNED					
14. DATE OF CURRENT IL	LNESS, INJURY, or PREG	NANCY (LMP) 15	S. OTHER DATE	MM , DD ,	YY	16. DATES PATIENT I	UNABLE TO WO	RK IN CURRE	ENT OCCUPATION		
	QUAL	٥	UAL.	MM I DD	**	FROM		TO			
17. NAME OF REFERRING	PROVIDER OR OTHER S	1	7a. 7b. NPI			18. HOSPITALIZATION	D DATES RELAT	ED TO CURP	DD YY		
19. ADDITIONAL CLAIM IN	FORMATION (Designated		7b. NPI	-		FROM 20. OUTSIDE LAB?		TO \$ CHARG	3FS		
						YES	NO		1		
21 DIAGNOSIS OR NATU	RE OF ILLNESS OR INJUR	IY Relate A-L to se	rvice line below (24E)	ICD Ind.		22 RESUBMISSION CODE	, ORIC	SINAL REF. N	0.		
A. L	В. L	_ с		D		23 PRIOR AUTHORIZ	ZATIONI NUMBER				
E 1	F. L	G.		H L		23. PHION AOTHORIZ	ATION NUMBER				
24 A. DATE(S) OF SE	RVICE B. To PLACE OF	C. D PROC	EDURES, SERVICES	OR SUPPLIES	E DIAGNOSIS	F.	G. H.	1	J.		
MM DD YY MI	I DD YY SERVICE	EMG CPT/HC	otain Unusual Circums	ODIFIER	POINTER	\$ CHARGES	OR Family UMITS Plan	ID. QUAL	PROVIDER ID. #	,	
1 1 1		(c)	(\mathbf{D})		(E)	1	(F)	NPI			
								MPT			
								NP)			
100											
	1 1							NPI			
	111					1		NPI			
								NPI			
1 1	1 1		1								
25. FEDERAL TAX I.D. NUI	MBER SSN EIN	26. PATIENT'S	ACCOUNT NO.	27. ACCEPT AS	SIGNMENT?	28. TOTAL CHARGE	29 AMO	NPI JNT PAID	30. Rsvd for NUC	CCHee	
		30		YES YES	NO NO	\$	\$		SS. Flave for NGC	U36	
31. SIGNATURE OF PHYSI INCLUDING DEGREES	CIAN OR SUPPLIER	32. SERVICE F	ACILITY LOCATION			33. BILLING PROVIDE		()	-		
(I certify that the statemi apply to this bill and are	ints on the reverse							. ,			
	a plat indicot.)										
		a.				8					



IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.

WARNINGS AND PRECAUTIONS

- Infusion-Related and Hypersensitivity Reactions: Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
- Infections: Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.
- Progressive Multifocal Leukoencephalopathy (PML): PML, a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported. Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms that may include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently.

- **Liver Injury:** There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
- Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all
 patients should be brought up to date with all immunizations according
 to current immunization guidelines. Patients receiving ENTYVIO may
 receive non-live vaccines and may receive live vaccines if the benefits
 outweigh the risks.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.

DRUG INTERACTIONS

Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers.

INDICATIONS

Adult Ulcerative Colitis (UC):

ENTYVIO is indicated in adults for the treatment of moderately to severely active UC.

Adult Crohn's Disease (CD):

ENTYVIO is indicated in adults for the treatment of moderately to severely active CD.

DOSAGE FORMS & STRENGTHS:

- ENTYVIO Intravenous (IV) Infusion: 300 mg vedolizumab
- ENTYVIO Subcutaneous (SC) Injection: 108 mg vedolizumab

Please click for Full Prescribing Information.

